Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Condoliase
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Ferring Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Ferring Plans FDA Advisory Meeting for SI-6603 in Lumbar Disc Herniation Treatment
Details : SI-6603 (condoliase) is an GAG-degrading enzyme investigational product being studied for the treatment of radicular leg pain associated with lumbar disc herniation (LDH) in adults.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
December 02, 2024
Lead Product(s) : Condoliase
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Ferring Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SI-614
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Ora, Inc | Statistics & Data Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 09, 2022
Lead Product(s) : SI-614
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Ora, Inc | Statistics & Data Corporation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Diclofenac Conjugated Sodium Hyaluronate
Therapeutic Area : Musculoskeletal
Study Phase : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Agreement
Eisai and Seikagaku Enter into Agreement for the Co-development and Marketing Alliance of SI-613
Details : The companies will jointly develop SI-613 in China for knee osteoarthritis. After obtaining approval, Seikagaku will supply products to Eisai, and Eisai will be responsible for distribution.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 04, 2020
Lead Product(s) : Diclofenac Conjugated Sodium Hyaluronate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Sponsor : Eisai
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : SI-722
Therapeutic Area : Urology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
PK and Safety of SI-722 in IC/BPS
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 23, 2019
Lead Product(s) : SI-722
Therapeutic Area : Urology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SI-6603
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SI-6603 (Condoliase) Study for Lumbar Disc Herniation (Discovery 6603 Study)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 31, 2018
Lead Product(s) : SI-6603
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SI-613
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Chiltern International
Deal Size : Inapplicable
Deal Type : Inapplicable
SI-613 Study for Knee Osteoarthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 06, 2017
Lead Product(s) : SI-613
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Chiltern International
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Condoliase
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of SI-6603 in Patients With Lumbar Disc Herniation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
April 20, 2015
Lead Product(s) : Condoliase
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SI-614
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 31, 2014
Lead Product(s) : SI-614
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Condoliase
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of SI-6603 in Patients With Lumbar Disc Herniation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 13, 2013
Lead Product(s) : Condoliase
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SI-614
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 20, 2012
Lead Product(s) : SI-614
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable